ADC TOXICITY ATLAS
AtlasPayloads and LinkersPayloadsTargetsMethods
← Atlas

XNW-27011

Investigational
XNW27011; XNW 27011
Sponsor
Evopoint Biosciences (Suzhou Sinovent Pharmaceuticals / Shanghai Sinovent Biopharmaceutical); licensed to Astellas (May 2025)
Indication
Claudin 18.2-positive gastric / gastroesophageal junction (GEJ) cancer (also solid tumors incl. pancreatic, ovarian)
Target family
Claudin / tight-junction
RP2D dose
-
Q3WPooled
01
Multi-organ toxicity

Fingerprint & organ drill-down

Also reported
0%severity100%
0
Assessed · clear
true 0%
No data
never assessed
1 adverse-event term

Ocular

Any-grade
0%
G3+
0%
Pooled
sagittal schematic · -
↳

Tissues shaded by reported adverse-event rate.

Cornea
AE
-
Express.
-
Limbus
AE
-
Express.
-
Conjunctiva
AE
-
Express.
-
Lens
AE
-
Express.
-
Retina / RPE
AE
-
Express.
-
Dominant tissue
-
Surface subtype
None
Reversibility
-
Reported ocular events
Ocular adverse events (any, explicitly assessed)0%
n=16
02
Construct

Molecular anatomy

Antibody
Humanized
Linker
Peptide
Cleavable
8
DAR
Payload
YL0010014
DNA topoisomerase 1 (TOP1) inhibition
Linker structureC30H49N7O4
CCCN(CCC)CCCC[C@H](NC(=O)C(NC(=O)CCCC#Cc1cncnc1)C(C)C)C(=O)NCC(=O)NC
Payload structureC24H22N2O7
CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=C(C5=CC6=C(C=C5N=C4C3=C2)OCO6)CCCO)O
03
Antibody

Antibody & Fc engineering

Antibody
Undisclosed (anti-CLDN18.2 monoclonal antibody)
Isotype
-
Origin
Humanized
Fc modifications
-
Glycoengineering
-
Effector silencing
-
FcγR binding
Retained
C1q binding
Retained
04
Linker & conjugation

Linker chemistry

Linker profile
Linker
Tumor microenvironment activable tripeptide linker
Class
Peptide
Cleavage
Cleavable
Attachment
-
Conjugation
-
Symmetry
-
DAR (mean)
8
DAR homogeneity
-
Plasma t½
-
Cleavage trigger
Tumor-microenvironment activatable (cleavable tripeptide linker)
Release control
N/A
Hydrophilicity mask
Unknown
Formula
C30H49N7O4
Linker MW
571.767 Da
Linker TPSA
145.42 Ų
Linker xLogP
1.7785
ADCdb linker
LIN0MDVFB
In-vitro stability
-
05
Payload

Payload & physicochemistry

Payload profile
Payload
YL0010014
Class
Topoisomerase I inhibitor
Mechanism
DNA topoisomerase 1 (TOP1) inhibition
Released catabolite
YL0010014 (topoisomerase-1 inhibitor payload) released via tumor-microenvironment-activatable tripeptide linker
Mechanistic subtype
TopoI
Stereochem / salt
-
Bystander
Yes
PAMPA rank
-
MW
450.4 Da
XLogP3
0.7
logD₇.₄
-
TPSA
118 Ų
pKa
-
Charge pH 7.4
0
H-bond donors
2
H-bond acceptors
8
IC50 (HCEC)
-
Formula
C24H22N2O7
PubChem CID
164872962
ADCdb payload
PAY0HNGJG
Bioactivity note
Payload YL0010014 is a DNA topoisomerase 1 (TOP1) inhibitor (per ADCdb payload PAY0HNGJG mechanism field); it is a camptothecin/FL118-class warhead (10,11-methylenedioxy-camptothecin scaffold with 3-hydroxypropyl substituent). No numeric IC50 reported on the ADCdb ADC or payload
06
Dosing & regimen

Dosing

RP2D dose
-
Schedule
Q3W
Route
IV
Fractionated
No
n at RP2D
-
Dose basis
-
Trial phase
Phase 1/2
Dose-OAE available
-
Tox summary basis
dose-escalation
07
Ocular & expression

Ocular profile & eye-tissue target expression

Target profile
OAE any-grade
0 %
OAE grade 3+
0 %
OAE data status
documented-absent
Severity (weighted)
0
Keratopathy
-
Conjunctival
-
Dry eye
-
Blurred vision
-
Dominant tissue
-
Surface subtype
None
Grading scale
CTCAE (unversioned)
Reversibility
-
Target expression in eye tissues (HCA detection · HPA bulk)
Cornea (central)
-
Cornea (limbal)
-
Conjunctiva
-
RPE
-
Retina (HPA)
-
Cross-trial comparability · source-verified
Ascertainment: Systematic eye examsScale: CTCAE (unversioned)Denominator: RP2D
08
Identity & registry

Identifiers, registry & notes

ADC id
xnw-27011
Approval status
Investigational
Approval year
-
UniProt
P56856
ADCdb ADC
DRG0FKZGF
ADCdb antibody
-
ADCdb target
TAR0IBZAS
Primary source
Annals of Oncology 2024 abstract 651P (S0923-7534(24)02236-1); ASCO 2025 abstract 3034 (JCO 43:16_suppl:3034)
Aliases & development codes
XNW27011; XNW 27011
Notes
XNW-27011 (XNW27011) is an anti-CLDN18.2 ADC with a novel topoisomerase-1 inhibitor payload (YL0010014, the same TOP1i payload class used in YL201) on a tumor-microenvironment-activatable cleavable tripeptide linker (ADCdb LIN0MDVFB), DAR 8. Sponsor Evopoint Biosciences (Suzhou/Shanghai Sinovent); licensed to Astellas May 2025; Phase 3 in advanced gastric cancer initiated. OCULAR ANCHOR (honored): Triage confirmed explicit-zero. Annals of Oncology 2024 abstract 651P Phase I dose-escalation narrative states verbatim: "No ILD or MMAE-related ocular AEs and peripheral neuropathy were observed." Ocular AEs explicitly assessed and ABSENT, so oae_any_pct=0 with documented note; ocular_surface_subtype=None. Topo-1/camptothecin-class payload is a low-ocular-risk class, consistent with the zero signal. DATA LIMITATIONS: The full all-grade treatment-related AE term table (specific percentages for neutropenia, thrombocytopenia, anemia, nausea, vomiting, AST/ALT, infusion reactions) is paywalled/embargoed across all accessible sources (Annals of Oncology fulltext 403; ASCO/JCO 3034 403; Larvol/ApexOnco mirrors 403). Therefore Hepatic/Hematologic/GI/Infusion toxicity_rows with quantified rates could NOT be populated — only the three explicitly-documented absent findings (Ocular=0, ILD=0, peripheral neuropathy=0) are recorded. Dosing: 0.6-6.0 mg/kg Q3W IV (accelerated titration then 3+3), n=16 across 6 cohorts as of 2024-04-15; ASCO 2025 gastric/GEJ cohort reported ORR ~46.7% (2.4/3.0/3.6 mg/kg) and DCR 88%; one death from pneumonia noted in input narrative. RP2D not disclosed in accessible abstracts, so rp2d_dose left blank and the RP2D-context rows are tagged line_context="RP2D" against the dose-escalation safety narrative. PAYLOAD PHYSCHEM: YL0010014 is a novel proprietary topo-1/camptothecin-class payload; PubChem-computed MW/xLogP3/logD7.4/TPSA/pKa/charge are not publicly indexed for this specific compound, so those cells are blank (not imputed) per the no-fabrication convention; only the qualitative bystander attribute (Yes, camptothecin-class) is given. Linker physchem fully captured from ADCdb.